Successfully Added to Cart

Updated Cart Total: 0 items Subtotal: €0,00 EUR
View Cart

Customers also bought...

    Zymo Research's 100% Satisfaction Guarantee

    Satisfaction Guaranteed

    Read The Zymo Research Promise

    Quick SARS-CoV-2 rRT-PCR Kit


    Zymo Research's 100% Satisfaction Guarantee

    Satisfaction Guaranteed

    Read The Zymo Research Promise

    Cat # Name Size Price Quantity
    R3011 Quick SARS-CoV-2 rRT-PCR Kit 100 rxns €1.282,00
    - +
    R3011-1K Quick SARS-CoV-2 rRT-PCR Kit 1,000 rxns €12.819,70
    - +
    R3011-10K Quick SARS-CoV-2 rRT-PCR Kit 10,000 rxns €128.196,50
    - +

    Highlights

    • Approved for emergency use authorization (EUA) by the U.S. Food and Drug Administration and CE-IVD certified.
    • High Sensitivity: Ranked among the top three most sensitive EUA tests by the FDA, with a Limit of Detection as low as 250 GEC/ml (15 GEC/reaction).
    • Specific: Detection of SARS-CoV-2 and Emerging Strains (including Omicron)
    • Rapid & Easy Setup: Ready-to-use Master Mix, just add sample.
    • Compatible with Automated and High-Throughput workflows.
    Description & Documents Specifications FAQ

    Documents

    Instructions for Use: 
    Patient Fact Sheet: 
    Healthcare Provider Fact Sheet: 
    KingFisher™ Script: 
    Supplemental Info

    Product Description

    The Quick SARS-CoV-2 rRT-PCR Kit is a real-time reverse transcription PCR (rRT-PCR) test for the qualitative detection of RNA from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for the coronavirus disease (COVID-19).

    The Quick SARS-CoV-2 rRT-PCR Kit detects N1, N2, and N3 regions of the viral nucleocapsid (N) gene and a host-specific target region (human RNase P gene) to assess sample quality. The kit also includes CV Positive Control that enable assay performance monitoring, and a No-Template Control to confirm the absence of contamination in the reagents.

    The Quick SARS-CoV-2 rRT-PCR Kit can be used on purified RNA samples isolated from upper respiratory and lower respiratory systems.

    The Quick SARS-CoV-2 rRT-PCR Kit has High Sensitivity, with a Limit of Detection as low as 15 viral genome equivalent copies per reaction, a fast turnaround time of less than 1.5 hours, and a simple workflow in which RNA is simply added to the Quick SARS-CoV-2 rRT-PCR Kit reagents and directly analyzed.

    Due to its simplicity, set-up up can be performed in an automation and it is compatible with high-throughput platforms. The kit is compatible with multiple Real-Time PCR instruments and technical support is available for all steps of the setup process and data interpretation.

    Learn More

    In the United States:

    -This test has not been FDA cleared or approved;
    -This test has been authorized by FDA under an EUA for use by authrized laboratories;
    -This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
    -This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner

    Qualitative assay for use on the Bio-Rad CFX96 Real-Time PCR Detection System. For use under the FDA Emergency Use Authorization (EUA) only. For in vitro diagnostic use.

    Documents

    Technical Specifications

    Compatibility Compatible with automated and high-throughput workflows.
    Equipment Required Real-Time PCR Instruments capable of detecting HEX™ and Quasar® 670/Cy5 fluorophores.
    Input Quality Purified RNA free of enzymatic inhibitors.
    Processing Time ≤ 1.5 hours from set up to results.
    Reagents Complete and ready to use master mixes.
    Registration Status FDA-Emergency Use Authorization
    CE-IVD certified
    Sample Input Material Purified RNA samples isolated from upper respiratory and lower respiratory systems.
    Supplemental Info

    Resources

    This test has been authorized by the U.S. FDA under an EUA and CE-IVD certified for use by authorized laboratories. In the U.S. this test is only authorized for the duration of that circumstances exist justifying the authorization of emergency use of in vitro diagnostic test for detection and/or diagnosis of COVID-19 under Section 564(b)(I) of the Act, 21 U.S.C. § 360bbb-3(b)(I), unless the authorization is terminated or revoked sooner.

    This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other virus or pathogen.

    Please refer to the Interpretation of Results, the Appendix, and the Troubleshooting Guide sections in our Quick SARS-CoV-2 rRT-PCR Kit protocol. If you still have problems with the result interpretation please contact our Technical Support team at (949) 679-1190 ext. 3 or e-mail us at tech@zymoresearch.com.

    Sometimes aberrant qPCR signal are observed. Please refer to the Interpretation of Results, the Appendix, and the Troubleshooting Guide sections in our Quick SARS-CoV-2 rRT-PCR Kit protocol. If you still have problems with the result interpretation please contact our Technical Support team at (949) 679-1190 ext. 3 or e-mail us at tech@zymoresearch.com.

    This may indicate incorrect plate set-up or a contamination in the No-Template Control or in the CV Mix 1 and/or 2. We recommend to use a new aliquot of reagents.

    This may indicate incorrect plate set-up or the compromise of Quick SARS-CoV-2 reagents. We recommend to use a new aliquot of reagents.

    If the host target didn’t amplify or shows CT values above 40, your RNA extraction and/or RT-PCR reaction may have been incorrectly performed. We suggest repeating RNA extraction and the RT-PCR reaction.

    Late signal for SARS-CoV-2 viral targets may be indicative of a low viral load in your sample. We suggest repeating the RT-PCR to confirm results.

    Viral and human targets are amplified in two separate reactions in order to prevent potential competition between PCR. Detecting viral and human targets in two separate reaction minimizes false negative results even in samples with extremely low viral titer.

    With a limit of detection(LoD) as low as 15 GEC/reaction the Quick SARS-CoV-2 rRT-PCR Kit outperforms most of the SARS-CoV-2 molecular tests present on the market.
    In addition, the detection of a host target (human Rnase P) allow the identification of insufficient samples, which other tests may classify as negative; this further reduce the chances of the false negative results.

    Need help? Contact Us